Financial Report: Pfizer 3Q

Pfizer

3Q Revenues: $14.0 billion (-16%) 

3Q Earnings:  $3.2 billion (-14%)

YTD Revenues: $43.9 billion (-11%)

YTD Earnings: $8.3 billion (-4%)

Comments: Biopharma revenues were $12.1 billion in the quarter, down 18%. Primary care revenues were down 39% to $3.6 billion. Specialty care revenues were $3.4 billion down 10%. Established products sales were up 7% to $2.4 billion. U.S. revenues were $5.6 billion, down 18% and International revenues were $8.3 billion, down 14%, primarily due to the loss of exclusivity of Lipitor (down 71% to $749 million) and the unfavorable impact of foreign exchange of $699 million, or 4%. Lyrica sales were up 14% to $1.0 billion. Prevnar 13/Prevenar 13 sales were down 14% to $868 million. Celebrex sales were up 7% to $676 million. Viagra sales were up 7% to $517 million.